- Exposure to higher amounts of fine particulate air pollution was associated with a greater likelihood of having chronic kidney disease.
- This link was stronger in urban areas, males, younger adults, and adults without comorbid diseases.
Washington, DC (December 17, 2020) -- New research indicates that people may face a higher risk of developing kidney disease if they live in areas with elevated air pollution. The findings appear in an upcoming issue of JASN.
Exposure to tiny particles of air pollution--called fine particulate matter--is known to increase people's risk for developing cardiopulmonary diseases, but its effects on kidney health are unclear.
To investigate, a team lead by Luxia Zhang, MD, MPH and Shaowei Wu, MD, PhD (Peking University) analyzed survey data from 47,204 adults in China and estimated 2-year air pollution levels at each participant's residential address from satellite-based information.
Approximately 10.8% of participants had chronic kidney disease. Each 10 μg/m3 increase in the concentration of fine particulate matter at a participant's address was associated with a 1.3-times higher odds of having the disease. This link was significantly stronger in urban areas, males, younger participants, and participants without comorbid diseases.
"Although ambient air quality has improved substantially during the past 5 years in China, the national annual particulate matter level in China exceeds the World Health Organization's guideline," said Dr. Zhang.
The authors noted that the findings provide evidence to policy makers and public health officials for the need for stricter air quality control measures to help protect individuals' kidney health.
Study co-authors include Guoxing Li, PhD, Jing Huang, PhD, Jinwei Wang, PhD, Ming-Hui Zhao, MD, PhD, Yang Liu, PhD, and Xinbiao Guo, PhD.
Disclosures: The authors reported no relevant financial disclosures.
The article, titled "Long-Term Exposure to Ambient PM2.5 and Increased Risk of CKD Prevalence in China," will appear online at http://jasn.asnjournals.org/ on December 17, 2020, doi: 10.1681/ASN.2020040517.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit http://www.asn-online.org.
Journal of the American Society of Nephrology